Related Experiment Video
Updated: Mar 8, 2026
08:15
Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System
Published on: April 11, 2025
993
Complex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis
Kelby W Wegner1, Danish Saleh2, Alexei Degterev3
1Master of Science in Biomedical Sciences Program, Tufts University School of Medicine, Boston, MA 02111, USA.
Trends in Pharmacological Sciences
|January 28, 2017
Summary
Necroptosis, a regulated cell death pathway involving RIPK1 and RIPK3 kinases, contributes to inflammation and disease. Targeting necroptosis mediators offers potential therapeutic strategies for various pathologies.
Area of Science:
- Molecular Biology
- Immunology
- Pathology
Background:
- Necroptosis is a regulated form of necrosis implicated in numerous pathological conditions.
- The formation of the necrosome complex, involving RIPK1 and RIPK3, is central to necroptosis.
- MLKL phosphorylation by RIPK3 is a key downstream event in necroptosis.
Purpose of the Study:
- To review the current understanding of necroptosis.
- To explore the role of necroptosis mediators in human diseases.
- To discuss potential therapeutic strategies targeting the necroptosis pathway.
Main Methods:
- Literature review of necroptosis research.
- Analysis of the molecular mechanisms of necroptosis.
- Examination of the involvement of necroptosis in various pathologies.
Main Results:
- Necroptosis is a significant driver of cell death and inflammation in disease.
- RIPK1, RIPK3, and MLKL are core mediators of necroptosis.
- These mediators also possess non-necroptotic functions in apoptosis and inflammation control.
Conclusions:
- The necroptosis pathway is relevant to a wide range of human diseases.
- Targeting necroptosis mediators presents promising therapeutic avenues.
- Further research into the complex roles of these mediators is warranted.
More Related Videos
08:55Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis
Published on: August 7, 2018
11.4K
09:15Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
Published on: October 20, 2022
2.9K
Related Concept Videos
01:16Necrosis
7.0K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
7.0K
01:17The Extrinsic Apoptotic Pathway
9.1K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
9.1K
01:31Regulation of the Unfolded Protein Response
3.1K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
3.1K
01:30Overview of Cell Death
10.7K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
10.7K
01:32Export of Misfolded Proteins out of the ER
5.4K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.4K
01:22PI3K/mTOR/AKT Signaling Pathway
6.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.1K